

VEGA DAILY

Unlock Your Best Quotation
Ask VEGA Now!

May 14, 2025

VITAMIN

01

On May 13, market sources reported that Zhejiang Changhai Pharmaceuticals Co., Ltd. plans to halt its Vitamin E production facility for a 3-month maintenance period, expected to begin in early June and conclude in early September.

Recently, the kick-off and implementation plan review meeting for the National Key R&D Program "Synthetic Biology" project titled "Efficient Heterologous Synthesis of Vitamins," led by Sichuan University and Zhejiang Garden Biopharmaceutical Co., Ltd., was successfully held in Chengdu. Nanjing Tech University and Jiangnan University also participated in the collaboration. The meeting marked the official commencement of the project's full-scale implementation. The team will delve into the field of vitamin biosynthesis, fostering collaborative innovation to achieve breakthroughs in vitamin biosynthesis and contribute to the development of China's biomanufacturing industry.

AMINO ACID

02

Valine: Chinese manufacturers have raised their quotations, creating a positive market atmosphere. The trade market price ranges between **USD 1.6-1.66/KG**, with end-s primarily purchasing based on immediate needs. The valine market is expected to remain strong in the short term, with firm factory quotations. It is advisable to monitor factory order progress closely.

API

03

The market price of **Doxycycline Hydrochloride** has continued to rise this week, primarily due to reduced factory capacity and increased market demand. After a continuous decline in the first quarter, the market price has rebounded significantly since the end of the first quarter, driven by rising upstream raw material costs. The previous market transaction was around **USD 44.25**, and further changes should be monitored. Recently, Rundu Pharmaceutical (Jingmen) Co., Ltd. received the veterinary drug product approval license for "Florfenicol" (non-sterile raw material) issued by the Ministry of Agriculture and Rural Affairs of China.

FOOD ADDITIVE

04

Sel Biochem Xinjiang Co., Ltd. has announced detailed plans for its biopharmaceutical industry upgrade and transformation project. A new Coenzyme Q10 production line will be established in the Tianfu High-Tech Park of the Shihezi Economic and Technological Development Zone, with an expected annual output of 500 tons of Coenzyme Q10. The total investment is USD 10.67 million .

Sel Biochem Xinjiang Co., Ltd. was established in 2010 in Shihezi, Xinjiang, jointly funded by Xinjiang Tianfu Energy Co., Ltd. and Sel Biochem Jiangsu Co., Ltd., a subsidiary of Zhejiang University Sunny Technology Co., Ltd. In 2019, Sunny Biotech Hangzhou Co., Ltd., a subsidiary of Zhejiang University Sunny Technology Co., Ltd., acquired 100% of the shares of Xinjiang Tianshu Sunny Biotech Co., Ltd. The company is primarily engaged in the research and production of bio-veterinary drug intermediates, bio-feed additives, and other agricultural biotech products.

Reported by Candice, Shea and Sharon

ONE STOP SOLUTION SUPPLIER

